Background: MEDI4893 is an anti-alpha toxin (AT) antibody currently in clinical trial in the field of Staphylococcus aureusmediated diseases.
Introduction
Staphylococcus aureus utilizes a wide array of virulence factors to infect humans and cause disease worldwide. S. aureus infections range from mild skin and soft-tissue infections to serious invasive diseases such as endocarditis, sepsis, and necrotizing pneumonia (1, 2) . Isolates are commonly classified based on susceptibility to methicillin, although several reports showed that infections result in serious outcomes regardless of resistance status (3, 4) . This makes therapeutic intervention difficult and expensive.
Currently, antibiotics are the standard of care for treating S. aureus diseases. However, upon introduction of new antibiotics, the pathogen often develops new resistance mechanisms requiring novel approaches to prevent or treat S. aureusrelated diseases.
S. aureus alpha toxin (AT), a water soluble ~ 33 kDa molecule, exerts its virulence upon binding to its receptor (ADAM10) on the surface of platelets, monocytes, lymphocytes and endothelial cells (5) . Following binding to ADAM10, toxin molecules undergo a conformational change to favor oligomerization resulting in the formation of membrane-disrupting pores. Cell lysis and tissue damage then follow (6) . Targeted inhibition of AT binding to its receptor and/or of pore formation could prevent or limit S. aureus-related diseases. This hypothesis is supported by studies demonstrating reductions in S. aureus-related disease severity in murine infection models following active or passive immunization directed against AT (7, 8, 9, 10, 11) .
The X-ray crystal structure of the AT heptameric complex has been reported and resembles two fitted cylinders of different diameters with lengths of ~ 70 and 50 Ǻ each, and a combined length of ~ 100 Ǻ (12). The wider cylinder comprises the so-called 'cap' and 'rim' domains from each protomer, while the narrow cylinder is made of their so-called 'stem' regions. The N-terminal 20 amino acids of each cap domain create a "latch" that interacts with neighboring molecules and locks them in the heptamer conformation. Each of the monomers also contributes 2 -strands to the stem, thus making the heptamer a 14-stranded anti-parallel β-barrel. The rim domains appear to be proximal to the membrane as they are directly involved in AT binding to cells (13) . In another structural study, the complex between the Fab fragment of an inhibitory anti-AT antibody (mAb LTM14) and an AT monomer revealed an epitope spanning the cap and rim domains. A mechanism of action for this mAb based upon blocking the AT/ADAM10 interaction was consequently suggested (14) .
Other potent inhibitory anti-AT mAbs have recently been described, which modulate the host's immune response and improve disease outcome in murine dermonecrosis models (11, 15) . These attractive properties led to the development by MedImmune of MEDI4893, a human anti-AT mAb containing the 'YTE' substitutions in its Fc region to enhance serum half-life (16, 17) . MEDI4893 is currently in a Phase I clinical trial (www.clinicaltrials.gov). We have solved the X-ray crystal structure of the Fab fragment of MEDI4893 bound to monomeric AT at a resolution of 2.56 Ǻ. Coupled with binding studies to various AT variants, we have accurately defined this mAb's epitope and elucidated its interesting mechanism of action.
Experimental procedures

Reagents and conventions
All chemicals were of analytical grade.
Restriction enzymes and DNAmodifying enzymes were purchased from New England Biolabs, Inc. (Beverly, MA). Oligonucleotides were purchased from Operon (Huntsville, AL). LC10, anti-His mAb and anti-AT polyclonal antibodies were generated at MedImmune. All antibody and antigen amino acid positions mentioned in the text were identified according to a consecutive numbering scheme.
Crystallization, X-ray data collection, structure determination and refinement Crystallization and data collection have been described elsewhere (18) . The structure of monomeric AT bound to MEDI4893 Fab was determined by molecular replacement using a modified model of a AT protomer in the heptameric conformation (PDB ID number 7AHL, Ref. 12) , and that of an unpublished Fab structure (MedImmune). Phaser (19) found two complexes in the asymmetric part of the unit cell with a final Zscore above 20. Electron density calculated with the phases generated by Phaser showed very clean electron density for most parts of the molecules. Positive difference density showed missing portions of the model. Standard resolution cutoff based on intensities with signal/noise ratio greater or equal than -3.0 and completeness of over 90% was used. Additionally, based on visual inspection of electron density maps features, the resolution limit was set at 2.56 Å. Alternating cycles of refinement with REFMAC5 (20) and model building using "O" (21) were performed. During the refinement with REFMAC5, we used TLS parameters determined using the TLSMD server (22, 23) . The final refinement step was done using the PDB-REDO server (24). Refinement statistics are shown in Table  I .
Construction and expression of AT, LukF-PV and AT/LukF-PV variants
DNA constructs for 6 'knock out' (KO)
AT/LukF-PV chimeric variants encoding LukF-PV regions at amino acids 1-51, 52-110, 111-147, 148-205, 204-241 or 248-293 were generated by gene synthesis. Constructs encoding for the rest of the KO and 'knock-in' (KI) variants were created by overlapping extension PCR (25) using pET3d plasmids encoding AT or LukF-PV (MedImmune) as templates. The KI mutant denoted KI_173-201+261-272 encoded a Histag at his C-terminus and a FLAG-tag at its Nterminus. All DNA constructs were cloned into the pET3d bacterial expression vector and transformed into E. coli strain BL21 (DE3). All constructs were expressed by growing the transformed BL21 (DE3) cells in MagicMedia E. coli expression medium (Life Technologies, Grand Island, NY) using standard protocols.
ProteOn measurements
The binding affinity of LC10 to AT/LukF-PV chimeric variants was determined using a ProteOn XPR36 instrument (Bio-Rad, Hercules, CA). Standard amine coupling was used to immobilize anti-AT polyclonal antibodies in 10 mM sodium acetate, pH 5.0, to the surface of a ProteOn GLC biosensor chip at ~ 5,000 resonance units (RU) for each channel. KO variants in bacterial lysate supernatant were injected onto the immobilized sensor surface to obtain a capture response of ~ 200 RU. Untransformed bacterial lysate supernatant was also injected under the same conditions as a reference channel. LC10 samples were prepared in phosphate-buffered saline (PBS), pH 7.4, 0.005% Tween-20, and injected at 90 μL/min for 150-180 sec at concentrations ranging from 50-3.125 or 20-1.25 nM. 600-800 sec dissociation times were used. Expression levels of the variants were also monitored following the injection of LC10 as follows: anti-AT polyclonal antibodies were flowed at 90 μL/min for 150-180 sec at concentrations ranging from 50-3.125 nM with a 600-800 sec dissociation time. The KI mutant was captured using an anti-His monoclonal antibody and binding of LC10 assessed using the same conditions as described for the KO mutants. The expression level was monitored by injecting anti-flag polyclonal antibodies (Thermo Fisher Scientific, Waltham, MA) at 90 μL/min for 180 sec at concentrations ranging from 20-1.25 nM (series of 1:2 dilutions) with an 800 sec dissociation time. All surfaces were regenerated twice by injecting glycine 10 mM, pH 1.5, at 100 μL/min for 30 sec. All sensorgram data were processed with the ProteOn Manager 3.0.1 software and fit to a 1:1 binding model.
THP-1 cell binding assay
The effect of LC10 on AT binding to the monocytic cell line THP-1 was assessed by flow cytometry. The non-toxic AT mutant AT H35L was used to prevent cell lysis. AT H35L was biotinylated using the EZ link Sulfo-NHS-LC-Biotinylation kit (Thermo Fisher Scientific) following the manufacturer's instructions. LC10 or isotype control R347 IgG were mixed with AT H35L at a 2:1 (mAb:AT H35L ) molar ratio. 500 μL of THP-1 cells (5 x 10 6 /well) were blocked with a human Fc receptor binding inhibitor (BD Biosciences, San Jose, CA) for 1 h at RT. After 2 washes with ice cold PBS, the cells were incubated with the AT H35L /mAb mixture for 30 min at RT. Following 2 PBS washes, a streptavidin-Pacific blue conjugate (EBiosciences, San Diego, CA) was added and cells incubated for 30 min at RT. AT H35L binding was then assessed with a LSRII flow cytometer (BD Biosciences), and data analyzed with Flow Jo Software (Tree Star, Inc., Ashland, OR).
Results and Discussion
Determination of the three-dimensional structure of the AT/MEDI4893 Fab complex
In an effort to elucidate the epitope of MEDI4893 and gain understanding about the molecular basis for its neutralizing properties, we determined the crystal structure of the complex formed between monomeric AT and MEDI4893 Fab at 2.56 Ǻ resolution. At the time of structure determination, only heptameric AT coordinates were publicly available.
Those extended amino acids involved in inter-molecular interactions within the heptamer were removed for the molecular replacement procedure as it is incorporated in Phaser (19) in the CCP4 suite. Model building was performed using "O" (21). The structure was refined with Refmac5 (20) 
Structural analysis of the AT/MEDI4893 Fab complex
The AT/MEDI4893 Fab complex structure revealed that MEDI4893 Fab binds in the rim domain to a non-linear epitope made of two segments: N177 to R200 and T261 to K271 ( Figure 1A) . The AT molecule binds in the crevice between MEDI4893 Fab LC and HC ( Figure 1B Figure  3A ). Superimposition over the same C α atoms of monomeric AT presented here and from PDB ID number 4IDJ (14) , both bound to their respective Fab, yielded an r.m.s deviation of 0.9 Ǻ (Figure 3B ).
MEDI4893 Fab binds to the opposite side of the rim domain when compared with mAb LTM14 (Figure 3B ). In particular, AT R200 is a critical part of the interface with MEDI4893 Fab.
Interestingly, the same residue has long been known to be important for AT interaction with its membrane receptor (13) . Therefore, we propose that MEDI4893 Fab 'blocks' R200 and sterically prevents AT interaction with its receptor, ADAM10. Finally, we note that MEDI4893 Fab binding to AT's rim region also likely prevents neighboring AT molecules to occupy positions that may promote pore formation, as seen using a model of the AT/MEDI4893 Fab complex superimposed with an AT protomer within the heptameric pore ( Figure 4 ). This is in contrast with LTM14 epitope which is not occluded upon AT heptamer formation ( Figure  4 ).
Mapping the epitope of MEDI4893 using AT chimeric variants
Chimeric variants comprising portions of AT and another S. aureus cytotoxin, LukF-PV, were generated to further characterize the epitope of MEDI4893 Fab on AT. LukF-PV was selected as the chimeric partner due to its lack of recognition by MEDI4893 (Table II) and high structural homology (27). Indeed, superimposition of monomeric AT of this study with LukF structure corresponding to PDB ID number 1PVL over all C α atoms yielded an r.m.s deviation of 4.6 Ǻ. All binding studies described thereafter were carried out using LC10, a human IgG1 identical to MEDI4893 but for the presence of the 'YTE' motif in its Fc portion.
Chimeric 'knock-out' (KO) variants were generated by systematically replacing ~ 50 AT amino acids with their LukF-PV counterparts. Shorter regions within the 50 amino acid segments of interest were also replaced. Binding of LC10 to these variants was then characterized using the ProteOn platform (Table II and Figure 5 ). All chimeric constructs expressed to some level, with the exception of KO_73-81 (Table II) . In summary and in light of all KO variants and their respective binding affinity (or lack thereof) to LC10, we found that replacing any of the three regions corresponding to amino acids 101-110, 224-241 and 248-277 of AT with LukF-PV residues negatively impacted LC10 binding.
Replacing the remaining amino acids seemed to have no significant impact. These results are in general good agreement with the structural data presented here, as they identify one important AT stretch (248-277) comprising interface residues 261-271 (see previous section entitled 'Structural analysis of the AT/MEDI4893 Fab complex'). However, they also identify 2 additional AT stretches not part of the structural interface, namely 101-110 and 224-241. Conversely, KO data did not allow us to identify the structurally important 177-200 stretch (see previous section entitled 'Structural analysis of the AT/MEDI4893 Fab complex'). The three segments identified using KO variants can be mapped to 3 distinct locations in the AT structure ( Figure 6 ). Together, these regions are beyond the expected footprint of an antibody. Therefore, it is possible that the apparent importance of residues 101-110 and 224-241 be due to indirect effects, for instance mis-folding at (or near) LC10 epitope upon replacing the corresponding residues by their LukF-PV counterparts. It is also worth noting that the sequence homology between AT and LukF-PV varies substantially at different regions.
For example, the segments corresponding to AT residues 148-205 and 179-193 share 39 and 67% , respectively, identity with LukF-PV, while the entire sequence only shares 25%. In particular, the structurally important stretch corresponding to amino acids 177-200 of AT shares 55% identity with LukF-PV. Within that stretch, this identity extends to 3 out of the 6 residues in direct contact with MEDI4893, namely S186, Y191 and R200. Another contact residue, W187, exhibits strong conservation with its LukF-PV counterpart (F187). Therefore, when swapping such regions of high sequence homology, it is not surprising that LC10 binding not be significantly affected.
In order to further characterize LC10 epitope, we used a 'knock-in' (KI) approach whereby segments corresponding to AT amino acids 173-201 and 261-272 were introduced into LukF-PV. This created a chimeric LukF molecule containing LC10's entire 'structural' epitope. As seen in Table II , LC10 bound to this variant (KI_173-201+261-272) with a K D of 134 pM. This is within ~10-fold of that to AT and represents a significant gain of affinity when compared with LukF-PV. Therefore, AT residues within 173-201 and 261-272 were confirmed as both functionally and structurally important for LC10 binding.
MEDI4893 mechanism of action
Based on the co-crystal structure reported here, we hypothesize that MEDI4893 inhibits AT binding to its receptor. In order to confirm this additional mode of action under physiologically relevant conditions, a biotinylated, non-lytic AT mutant (AT H35L ) was treated with either LC10 or the isotype control R347 prior to incubation with a monocytic cell line (THP-1). AT binding to the cells was then detected by flow-cytometry. In this assay, in the presence of R347, AT H35L binds cells to a similar degree as AT H35L alone whereas LC10 completely abrogates AT H35L binding to the cells (Figure 7) . These results are in very good agreement with our structural findings and suggest that LC10 blocking of AT binding to its receptor constitutes a significant mode of action. We also find that MEDI4893 could potentially block oligomer formation by steric hindrance (see above and Figure 4 ). These two possible mechanisms of action provide a good molecular understanding for this antibody's ability to block AT heptamerization and prevent ATmediated cell lysis (11) .
In summary, we have characterized the epitope of a human antibody directed against AT and currently in clinical trials. We have shown that this mAb recognizes a novel epitope on AT's rim domain and deciphered a possible dual mechanism behind its neutralizing properties.
Such a detailed structural and functional understanding of this mAb's mode of action has important implications for the design of the next generation of antibodies targeting S. aureusrelated diseases.
Accession number
The atomic coordinates and experimental structure factors of AT/MEDI4893 Fab have been deposited with the Protein Data Bank under accession number 4U6V. The latch in our monomeric AT is modelled starting residue 12 due to the absence of corresponding electron density map, while those residues are stabilized through interaction with neighboring molecules in the pore-forming state. The AT stem in the pore-forming conformation is extended to make the β-barrel together with six other protomers, while in our monomeric conformation it is compactly folded into β-strands. 
